Abstract
Purpose :
To determine the prevalence of Vitreomacular traction syndrome in patients with Neovascular Age related Macular Degeneration.
Methods :
Retrospective, transversal, observational and descriptive study: Prevalence study
Results :
On the present study the prevalence of the Vitreomacular traction syndrome was divided within 4 different groups with choroidal neovascularization type 1, 2, 3,4/mixed and whether or not it had a macular scar secondary to a previous neovascularization. The results proved that there was a low prevalence of any type of Vitreomacular traction syndrome in combination with a Neovascular Age related Macular Degeneration diagnosis.
The prevalence of all types of Vitreomacular traction syndrome was of 12.1%, Vitreomacular adhesion 6.5% and vitreomacular traction 5.6%.
Conclusions :
To our knowledge, this is the first study that searches for the prevalence of the Vitreomacular traction syndrome in patients with Neovascular Age related Macular Degeneration.
Within our study group the prevalence of Vitreomacular traction syndrome was low, with a higher prevalence in the group of type I choroidal neovascularization and chronic stages of the disease with a subretinal scar. Other authors have found that the Vitreomacular traction syndrome alongside the Neovascular Age related Macular Degeneration results in a worse visual prognosis.
More studies are necessary regarding the Vitreomacular traction syndrome with Neovascular Age related Macular Degeneration to understand with more detail if the choroidal neovascularization has a higher risk of happening.
Nonetheless, this study helps us understand that even though the synergy of the Vitreomacular traction syndrome with Neovascular Age related Macular Degeneration could display a worse outcome of the disease, the prevalence of the two disease at the same time is low, and therefore the probability of a higher risk disease presentation is lower.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.